93 results
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
28 Mar 24
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
7:01am
differences in clinical sites and environment. Consistent with previously disclosed guidance and based on the current operating plan, cash and cash
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
13 Feb 24
Regulation FD Disclosure
4:00pm
, industry environment and potential growth opportunities, among other things. The results of earlier preclinical or clinical trials may
8-K
EX-99.1
vqs1f 0dn
19 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.1
inhg5siyy6i0b81zrd
28 Nov 23
Regulation FD Disclosure
7:16am
8-K
EX-99.1
45yf59gi
29 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
1b4lm7anyx
27 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
v5ywqk 62
15 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
ur8g 3t2mns
29 Nov 22
Other Events
8:05am
8-K
EX-99.1
tj5pwl8b
10 Nov 22
Results of Operations and Financial Condition
7:06am
8-K
EX-99.1
zcphmo
6 Oct 22
Regulation FD Disclosure
7:05am
8-K
EX-99.1
8mp1argq6u quyicp
14 Sep 22
Dry Eye Disease NDA for Reproxalap Expected to be Submitted in the Fourth Quarter of 2022
8:06am
8-K
EX-99.1
9stpa4
12 Jul 22
Regulation FD Disclosure
7:15am